Retinalamin Research for Glaucoma (Adjunctive)
An evidence-based overview of research examining Retinalamin in the context of glaucoma (adjunctive). This page synthesizes findings from peer-reviewed literature.
Research Summary
Used adjunctively in Russia for glaucomatous optic neuropathy to support retinal ganglion cell survival. Animal studies suggest anti-apoptotic effects on ganglion cells. Not a primary glaucoma treatment; used alongside IOP-lowering therapies. Limited clinical evidence.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Glaucoma (Adjunctive)
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Retinalamin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.